FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.
Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...
The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...
Ahead of Robert F. Kennedy Jr.’s confirmation hearings, experts—and RFK’s own family—expressed concerns about his ...
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results